Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce Liu

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Communications Medicine|May 16, 2024
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACsDonglu Zhang, Bin Ma, Peter S Dragovich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 7, 2016
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomasLauren L Ritterhouse, Jonathan A Nowak, Kyle C Strickland, et al.
Injury|May 11, 2025
Factors associated with discharge to home after traumatic rib fracturesJenniferM Brewer, JuliaR Silverman, Yuen-Joyce Liu, et al.
Drug Metabolism Reviews|July 4, 2024
Bioactivation and reactivity research advances - 2023 year in reviewShuai Wang, Upendra A Argikar, Maria Chatzopoulou, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Drug Metabolism Reviews|August 23, 2023
Bioactivation and reactivity research advances - 2022 year in review‡Shuai Wang, Upendra A Argikar, Lionel Cheruzel, et al.
Journal of Inherited Metabolic Disease|July 26, 2023
Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primatesKristen Skvorak, Joyce Liu, Nikki Kruse, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Communications Medicine|May 16, 2024
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACsDonglu Zhang, Bin Ma, Peter S Dragovich, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 7, 2016
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomasLauren L Ritterhouse, Jonathan A Nowak, Kyle C Strickland, et al.
Injury|May 11, 2025
Factors associated with discharge to home after traumatic rib fracturesJenniferM Brewer, JuliaR Silverman, Yuen-Joyce Liu, et al.
Drug Metabolism Reviews|July 4, 2024
Bioactivation and reactivity research advances - 2023 year in reviewShuai Wang, Upendra A Argikar, Maria Chatzopoulou, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
International Journal of Cancer|November 13, 2019
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancerAndrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, et al.
Drug Metabolism Reviews|August 23, 2023
Bioactivation and reactivity research advances - 2022 year in review‡Shuai Wang, Upendra A Argikar, Lionel Cheruzel, et al.
Journal of Inherited Metabolic Disease|July 26, 2023
Oral enzyme therapy for maple syrup urine disease (MSUD) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primatesKristen Skvorak, Joyce Liu, Nikki Kruse, et al.
Pageof 13